Literature DB >> 20735384

Expression of integrin proteins in non-muscle-invasive bladder cancer: significance of intravesical recurrence after transurethral resection.

Hosny M Behnsawy1, Hideaki Miyake, Medhat A Abdalla, Mohamed A Sayed, Abd El-Fattah I Ahmed, Masato Fujisawa.   

Abstract

OBJECTIVES: • To evaluate the expression of integrin proteins, a family of transmembrane heterodimers, in non-muscle-invasive bladder cancer (NMIBC). • To assess the significance of these proteins as prognostic indicators in patients undergoing transurethral resection (TUR). PATIENTS AND METHODS: • The present study comprised 161 patients diagnosed as having NMIBC after TUR. • Expression levels of six subunits of integrin proteins, including α2, α3, α5, α6, β1 and β4, were measured in TUR specimens by immunohistochemical staining.
RESULTS: • Of the six proteins, expression levels of α2-, α3-, α6- and β4-subunits were significantly associated with the incidence of intravesical recurrence. Univariate analysis identified expression levels of α3-, α6- and β4-subunits as important predictors of intravesical recurrence, while tumour size, pathological T stage and concomitant carcinoma in situ (CIS) were also important. • Multivariate analysis showed that the expression level of the β4 subunit, pathological T stage and concomitant CIS are independently related to intravesical recurrence. • There were significant differences in intravesical recurrence-free survival for patients who were positive for the three independent risk factors; intravesical recurrence occurred in 10 of 49 (20.4%) patients who were negative for all risk factors, 31 of 68 who were positive for one risk factor (45.6%), and 30 of 44 who were positive for two or three risk factors (68.2%).
CONCLUSIONS: • Consideration of the expression levels of integrins, particularly those of the β4 subunit, in TUR specimens, in addition to conventional variables, would contribute to accurate prediction of intravesical recurrence after TUR for NMIBC patients.
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20735384     DOI: 10.1111/j.1464-410X.2010.09534.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

Review 1.  Clinical significance of the integrin α6β4 in human malignancies.

Authors:  Rachel L Stewart; Kathleen L O'Connor
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

2.  Association between polymorphisms in the integrin gene predicted microRNA binding sites and bladder cancer risk.

Authors:  Jiaming Liu; Sihang Cheng; Yonggang Zhang; Hong Li; Jin Huang; Peng Zhang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer.

Authors:  Shingo Tsuji; Katherine Reil; Kinsey Nelson; Veronica H Proclivo; Kathleen L McGuire; Matthew J Giacalone
Journal:  Cancer Immunol Res       Date:  2022-08-03       Impact factor: 12.020

4.  Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines.

Authors:  Stefan Vallo; Jochen Rutz; Miriam Kautsch; Ria Winkelmann; Martin Michaelis; Felix Wezel; Georg Bartsch; Axel Haferkamp; Florian Rothweiler; Roman A Blaheta; Jindrich Cinatl
Journal:  Oncol Lett       Date:  2017-09-04       Impact factor: 2.967

5.  Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer.

Authors:  Takashi Sakaguchi; Hirofumi Yoshino; Masaya Yonemori; Kazutaka Miyamoto; Satoshi Sugita; Ryosuke Matsushita; Toshihiko Itesako; Shuichi Tatarano; Masayuki Nakagawa; Hideki Enokida
Journal:  Br J Cancer       Date:  2017-03-21       Impact factor: 7.640

6.  N6-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer.

Authors:  Huan Jin; Xiaoling Ying; Biao Que; Xiaoxue Wang; Yinghui Chao; Haiqing Zhang; Zusen Yuan; Defeng Qi; Shuibin Lin; Wang Min; Mei Yang; Weidong Ji
Journal:  EBioMedicine       Date:  2019-08-10       Impact factor: 8.143

7.  Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer.

Authors:  Shingo Tsuji; Xuguang Chen; Bryan Hancock; Veronica Hernandez; Barbara Visentin; Katherine Reil; Roger Sabbadini; Matthew Giacalone; W T Godbey
Journal:  Mol Ther Oncolytics       Date:  2016-03-16       Impact factor: 7.200

8.  Expression and Prognostic Analyses of ITGA3, ITGA5, and ITGA6 in Head and Neck Squamous Cell Carcinoma.

Authors:  Chen Feng; Xiaoxue Jin; Yingying Han; Ruixiang Guo; Juanjuan Zou; Yanzhong Li; Yan Wang
Journal:  Med Sci Monit       Date:  2020-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.